Distinguishing Lewy body dementias from Alzheimer's disease

Expert Review of Neurotherapeutics
Rawan Tarawneh, J E Galvin


Lewy body dementia (LBD) is the second most common dementia after Alzheimer's disease (AD). LBD is characterized clinically by visual hallucinations, extrapyramidal symptoms, cognitive fluctuations and neuroleptic sensitivity. LBD and AD share many common features in pathology, genetics and biochemical alterations; however, correct clinical distinction between these disorders has prognostic and therapeutic implications. There are currently no definitive radiological or biological markers for LBD, but studies suggest that premorbid differences in cognitive domains and personality traits, differences in clinical presentation, and alterations in autonomic function and sleep may improve diagnosis. Cholinergic dysfunction plays a major role in both AD and LBD; however, dysfunction is greater in LBD. This may account for the more prominent hallucinations, and offers the possibility of a greater response to cholinesterase inhibitors in LBD. The treatment of LBD is symptomatic and is based on a limited number of clinical trials and extension of results from trials in AD. Current research is focused on the role of synuclein aggregation with possible roles for synuclein-derived peptides as aggregation inhibitors. Other approaches target ...Continue Reading


Sep 19, 1992·BMJ : British Medical Journal·I McKeithE Perry
Nov 1, 1992·Psychological Medicine·I G McKeithE K Perry
Mar 1, 1992·Archives of Neurology·F G BózzolaS Freels
Feb 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·W R GibbP L Lantos
Aug 1, 1987·Journal of the American Geriatrics Society·E H RubinL Berg
Jan 1, 1981·Neurobiology of Aging·L J ThalH Crystal
Sep 26, 1995·Proceedings of the National Academy of Sciences of the United States of America·M YoshimotoT Saitoh
Jul 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·R BarberD Craufurd
Jan 1, 1995·Neurology·C F LippaD Dickson
Oct 1, 1994·Journal of Geriatric Psychiatry and Neurology·K V WildB S Oken
Apr 6, 1994·JAMA : the Journal of the American Medical Association·M J KnappS I Gracon
Apr 1, 1994·Journal of Geriatric Psychiatry and Neurology·G Oppenheim
Nov 1, 1993·Journal of Neuropathology and Experimental Neurology·L A HansenR D Terry
May 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·R A RoosE A van der Velde
Jul 1, 1996·Brain and Cognition·D P SalmonR Katzman
Jul 1, 1996·Brain and Cognition·D GalaskoL Hansen
Nov 15, 1996·Science·M H PolymeropoulosR C Duvoisin
Mar 1, 1997·Archives of General Psychiatry·D P DevanandY Stern
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Oct 20, 1998·International Journal of Geriatric Psychiatry·S H MacGowanM Scott
Nov 3, 1998·Lancet·C F LippaP St George-Hyslop
Jan 8, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A Nordberg, A L Svensson
Mar 14, 2000·International Journal of Geriatric Psychiatry·Z WalkerC L Katona
May 10, 2000·Neurology·O L LopezS T DeKosky
Aug 11, 2000·Microscopy Research and Technique·N Helbecque, P Amouyel
Aug 17, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·A SchragN Quinn

❮ Previous
Next ❯


Jul 30, 2010·The Gerontologist·Amanda N LeggettJames E Galvin
May 4, 2012·Cold Spring Harbor Perspectives in Medicine·Rawan Tarawneh, David M Holtzman
May 2, 2012·Alzheimer's Research & Therapy·Samuel E Marsh, Mathew Blurton-Jones
Jul 18, 2014·Alzheimer's Research & Therapy·Yael R Zweig, James E Galvin
Dec 18, 2013·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·David R LeeAlan J Thomas
Oct 22, 2011·Expert Review of Neurotherapeutics·Stella Karantzoulis, James E Galvin
Sep 26, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·James E Galvin
Oct 8, 2015·Scientific Reports·Ryan WalshHeather A Clark
Apr 24, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer G GoldmanJames E Galvin
Oct 24, 2013·International Journal of Geriatric Psychiatry·L F Morra, P J Donovick
Aug 24, 2013·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Carrie A CiroDavid Garrison
Dec 17, 2011·Brain Research Bulletin·Patrick A Lewis, Mark R Cookson
Sep 3, 2013·Alzheimer Disease and Associated Disorders·Kyle HurthNigel J Cairns
Jul 14, 2010·Alzheimer Disease and Associated Disorders·Sandi CuloBruce G Pollock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Acta Neuropathologica
Charles DuyckaertsMarie-Claude Potier
Movement Disorders : Official Journal of the Movement Disorder Society
Yun Ju Christine SongGlenda Margaret Halliday
© 2021 Meta ULC. All rights reserved